Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
CMMB
vs
S&P 500
CMMB
S&P 500
Over the past 12 months, CMMB has underperformed S&P 500, delivering a return of -66% compared to S&P 500's +12% growth.
Stocks Performance
CMMB vs S&P 500
Performance Gap
CMMB vs S&P 500
Performance By Year
CMMB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Chemomab Therapeutics Ltd
Glance View
Chemomab Therapeutics is a drug development company focused on serious inflammatory and fibrotic diseases, which are conditions where the immune system drives damaging scar tissue and organ injury. Its main work is developing CM-101, an experimental antibody designed to block a protein called CCL24 that helps recruit inflammatory cells and promote fibrosis. The company is still in the clinical-stage part of biotech, so it does not sell commercial medicines yet. Chemomab’s customers are not patients in the usual retail sense; its main counterparties are the healthcare system, regulators, and, eventually, larger pharmaceutical partners or hospitals if a drug reaches market. It makes money primarily by advancing drug candidates through clinical trials and, if successful, could earn revenue from licensing deals, development partnerships, and future product sales. Like most biotech firms, its value comes from turning scientific research into approved treatments. What makes Chemomab’s business model different is its focus on a very specific disease pathway rather than a broad drug portfolio. By targeting CCL24, it is aiming at the underlying biology of fibrosis and inflammation across several hard-to-treat diseases, including liver and autoimmune-related conditions. That gives the company a platform-style research strategy, but one that still depends heavily on clinical trial results and regulatory approval.